Sign In
Buy PRFX
$1.13
+0.130 (+13.00%)
At Close: Aug 04, 2026
Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch Inte
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
08:30am, Tuesday, 21'st Jul 2026
TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that its DeepSolar business unit will participate in Energy Tr
New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch New Capability Builds on Recently Completed Real-Wor
Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Util
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
08:30am, Thursday, 25'th Jun 2026
Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential
Why Is PRF Tech Stock Falling On Monday?
09:51am, Monday, 01'st Jun 2026
PRF Technologies (NASDAQ: PRFX) stock falls sharply Monday morning. Read why analysts see this as a market correction after Friday's 186% surge.
Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market dec
Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
08:00am, Tuesday, 28'th Apr 2026
Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation Milestone supports advancement of PRF'
Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 13.3%
04:10am, Wednesday, 01'st Apr 2026
PainReform Ltd. (NASDAQ: PRFX - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 68,090 shares, a decrea
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2
TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced a commercial collaboration agreement with Blade Ranger Ltd.
Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale Solar Asset in Israel Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base
08:30am, Wednesday, 11'th Feb 2026
TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (Nasdaq: PRFX) (“PRF” or the “Company”), through its DeepSolar™ AI-driven solar analytics business unit, today announced
Patent filing follows acceptance into the NVIDIA Connect Program Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for
